GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

divozilimab   Click here for help

GtoPdb Ligand ID: 13087

Synonyms: BCD 132 | BCD-132 | Ivlizi®
Approved drug Immunopharmacology Ligand
divozilimab is an approved drug (Russia (2023))
Compound class: Antibody
Comment: Divozilimab (BCD 132) is an anti-CD20 monoclonal antibody that was developed by Biocad.
No information available.
Summary of Clinical Use Click here for help
Divozilimab (Ivlizi®) was granted first approval by the Russian Ministry of Health in April 2023. This approval indicated divozilimab to treat relapsing multiple sclerosis. Divozilimab is also under clinical evaluation for the treatment of neuromyelitis optica and systemic scleroderma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05730699 Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) Phase 3 Interventional Biocad
NCT05726630 Clinical Study of Divozilimab in Patients With Systemic Scleroderma Phase 3 Interventional Biocad